**Core Concept**
Multiple Myeloma is a plasma cell malignancy characterized by clonal proliferation of malignant plasma cells in the bone marrow, leading to bone destruction, anemia, and renal failure. Genetic translocations involving the immunoglobulin heavy chain locus (IgH) on chromosome 14q32 are common in Multiple Myeloma and contribute to the disease's pathogenesis.

**Why the Correct Answer is Right**
The t(4;14) translocation is the most common adverse prognostic translocation in Multiple Myeloma, involving the IgH locus on chromosome 14q32 and the MMSET gene on chromosome 4p16. This translocation leads to the overexpression of the MMSET protein, which promotes cell proliferation, survival, and resistance to apoptosis. The MMSET protein also disrupts normal cellular functions, contributing to the aggressive behavior of the disease.

**Why Each Wrong Option is Incorrect**
**Option A:** t(11;14) translocation involves the IgH locus on chromosome 14q32 and the cyclin D1 gene on chromosome 11q13. While this translocation is associated with a relatively favorable prognosis, it is not the most common adverse prognostic translocation in Multiple Myeloma.

**Option B:** t(14;16) translocation involves the IgH locus on chromosome 14q32 and the MAF gene on chromosome 16q23. This translocation is associated with a poor prognosis, but it is less common than the t(4;14) translocation.

**Option C:** t(6;14) translocation involves the IgH locus on chromosome 14q32 and the cyclin D3 gene on chromosome 6q27. While this translocation is associated with a poor prognosis, it is not as common as the t(4;14) translocation in Multiple Myeloma.

**Clinical Pearl / High-Yield Fact**
The t(4;14) translocation is a significant prognostic factor in Multiple Myeloma, and its presence should prompt consideration of high-dose therapy and stem cell transplantation in eligible patients.

**Correct Answer:** C. t(4;14)